Table 3 FACIT- F and VAS outcomes

All Patients

60 (100)

33,50 ± 10,11

30,68–36,03

11–52

5,42 (0–9)

Sex

p = 0,58, t= -0,545 º

Female

44 (73,3)

33,07 ± 10,23

29,84–36,00

11–52

5,77 (0–9)

Male

16 (26,7)

34,69 ± 10,01

29,57–39,46

19–47

4,44 (0–8)

SARS CoV-2 infection

p = 0,009, t=-2,684 º

COVID +

8 (13,3)

25 ± 10,40

18–33,12

11–43

7,12 (3–9)

COVID -

52 (86,7)

34,81 ± 9,50

32,21–37,2

14–52

5,15 (0–9)

Type of anticancer therapy

p = 0,15, F = 1,80 ∞

Chemotherapy/Endocrine

23

33,87 ± 9,59

29,72–38,02

14–49

52 (86,7)

Immunotherapy

10

27,10 ± 10,08

19,89–34,31

11–44

6,50 (3–9)

Radiotherapy

4

34,50 ± 11,47

16,25–52, 6

19–45

6,00 (3–8)

Other or unknown

23

35, 74 ± 9,92

31,45–40,03

17–52

4,74 (0–9)

Comorbidities

p = 0,54, F = 0,72 ∞

Hypothyroidism

8 (13,3)

32,50 ± 10,78

23,48–41,52

11–45

6,88 (5–9)

Chronic pulmonary disease

3 (5,0)

31,33 ± 10,01

6,45–56,22

21–41

5,33 (3–8)

Depression

2 (3,3)

24,00 ± 5,65

-26,82–74,82

20–28

5,50 (3–8)

Metastatic disease

p = 0,075, t= -1,811 °

Yes

26

30,85 ± 11,17

26,65–35,26

11–52

5,73 (0–9)

No

34

35,53 ± 8,86

32,33–38,40

17–51

5,18 (0–9)